We have spent the last few days on what a vial contains: what a purity number measures, and why purity is not sterility. Here is the question underneath both. Where did the powder come from?
It sounds like paperwork. It is the whole ballgame.
The Law Asks Before The Pharmacy Mixes
A licensed compounder cannot just buy raw active pharmaceutical ingredient, or API, from whoever is cheapest. The FDA's standing guidance to compounders is to know your bulks and excipients suppliers, and it lists the conditions written into sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act: the API has to comply with an applicable USP or National Formulary monograph where one exists, or otherwise qualify under the statute (for 503A, by being a component of an approved drug or by appearing on the FDA's 503A bulks list), it has to be sourced from an FDA-registered facility, and it has to arrive with a valid certificate of analysis.
Every one of those is about provenance rather than chemistry. Registered facility means an address on file with the FDA, foreign or domestic, that the agency has authority to inspect. Monograph means a published identity standard somebody else wrote. Certificate of analysis means a document tied to a lot that can be traced backward. And that bulks list in the middle is the same list the July advisory committee was voting about.
What Goes Wrong Even Inside The System
The FDA publishes what it finds, which is the useful part. In September 2019 a US drug repackager shipped two lots of bulk powder labeled as quinacrine dihydrochloride to 14 pharmacies for compounding use. Testing identified the material as artemisinin, a different drug entirely, and the company issued a voluntary nationwide recall. The company reported no adverse events related to the recall, and the FDA's posting notes the recall was completed and terminated.
Read that as an argument against compounding if you like. We read it the other way. The wrong powder shipped, somebody tested it, two specific lot numbers were named, 14 known customers could be identified and notified, and the lots could be called back. Every step of that works only because there was a registered supplier, a lot number, and a list of who received it.
The Border Version Of The Same Question
The FDA applied the same logic at the port. In September 2025 it established a "green list" import alert for GLP-1 active ingredients: APIs from facilities the agency has inspected or evaluated may come in, and APIs from unverified foreign sources are subject to detention without physical examination.
That alert covers GLP-1 ingredients, not the peptides the FDA's Pharmacy Compounding Advisory Committee reviewed in July, and the two fights should not be blurred together. That July review also produced a recommendation, not a rule and not an approval: formal rulemaking with a public comment period still has to happen. But the principle travels. The government's screening question at the border is not what molecule is this. It is who made it, and did anyone check.
The Question Nobody Asks A Grey Market Seller
Now put that question to an anonymous vial ordered online. Which registered facility made the API. Which lot. Which monograph. Show the certificate, and show who audited the place that issued it.
There is no answer, because there is no address. That is not a chemistry failure. It is a supply chain that was built to be unanswerable.
That is Peppies' position, stated with our interest disclosed: we are an advocate for a legal, tested pathway, because a legal pathway is the only version where someone can be asked where the powder came from and has to answer. Track where that pathway stands on our regulatory tracker, read our safety coverage, and see the full disclosure at /about.
No peptide discussed here is FDA-approved. These products have not been evaluated by the FDA, and Peppies makes no claim that any peptide is safe or effective. Peppies does not sell peptides and is not affiliated with the FDA. Nothing here is medical advice. Talk to a licensed clinician.
Get notified when the next step in this process carries legal weight.
By Peppies.